2 citations
,
December 2023 in “Health Technology Assessment” Laser treatment and deroofing are effective options for hidradenitis suppurativa.
2 citations
,
August 2022 in “Cutis” COVID-19 vaccination may cause temporary nail changes, but they're not serious.
2 citations
,
January 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil for hair loss seems to have rare side effects, but more research is needed to confirm its safety.
2 citations
,
March 2018 in “Journal of The American Academy of Dermatology” Doctors should prescribe cheaper, off-label medication and teach patients how to use it to save money ethically.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
1 citations
,
April 2025 in “Dermatology and Therapy” Vitiligo's impact varies widely, affecting both emotions and social life, not just physical symptoms.
1 citations
,
July 2024 in “PharmacoEconomics - Open” The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
1 citations
,
January 2024 in “Nature communications” Activating TLR5 in the gut can extend lifespan and improve health in aged mice.
1 citations
,
January 2024 in “Annals of Dermatology” COVID-19 may trigger alopecia areata, but more research is needed.
1 citations
,
September 2023 in “Journal of drugs in dermatology” Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
1 citations
,
February 2021 in “Gastroenterology” A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
March 2026 in “Dermatology and Therapy” Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
Moderate facial angiofibroma significantly reduces quality of life compared to almost-clear cases, highlighting the benefits of treatment.
January 2026 in “Dermatology and Therapy” Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
November 2025 in “Health Promotion Evidence” Post-COVID-19 hair loss can be treated effectively with therapies like light therapy, microneedling, and scalp massage.
Apple cider vinegar rinses for synthetic hair extensions lack scientific proof of reducing harmful chemicals.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
Consider cultural practices and barriers for effective alopecia areata treatment.
April 2025 in “Dermatology and Therapy” Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.
March 2025 in “SKIN The Journal of Cutaneous Medicine” Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
January 2025 in “SKIN The Journal of Cutaneous Medicine” People with alopecia areata face different healthcare access and experiences based on their race and ethnicity.